Synthetic Biologics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch SYN and buy or sell other stocks, ETFs, and their options commission-free!

About SYN

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. 

CEO
Steven A. Shallcross, MBA, CPA
CEOSteven A. Shallcross, MBA, CPA
Employees
16
Employees16
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2001
Founded2001
Employees
16
Employees16

SYN Key Statistics

Market cap
22.56M
Market cap22.56M
Price-Earnings ratio
-0.29
Price-Earnings ratio-0.29
Dividend yield
—
Dividend yield—
Average volume
531.77K
Average volume531.77K
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$0.492
52 Week high$0.492
52 Week low
$0.1628
52 Week low$0.1628

Stock Snapshot

With a market cap of 22.56M, Synthetic Biologics(SYN) trades at $0.49. The stock has a price-to-earnings ratio of -0.29.

Synthetic Biologics(SYN) stock opened on 2026-10-24 at —. The price climbed to — and dipped to —.

The Synthetic Biologics(SYN)'s current trading volume is 0, compared to an average daily volume of 531.77K.

During the past year, Synthetic Biologics(SYN) stock moved between $0.16 at its lowest and $0.49 at its peak.

During the past year, Synthetic Biologics(SYN) stock moved between $0.16 at its lowest and $0.49 at its peak.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.